The cyclooxygenase-2 (PTGS2) 8473T⟩C polymorphism is associated with breast cancer risk

被引:72
作者
Langsenlehner, U
Yazdani-Biuki, B
Eder, T
Renner, W
Wascher, TC
Paulweber, B
Weitzer, W
Samonigg, H
Krippl, P
机构
[1] Med Univ Graz, Dept Internal Med, Div Oncogen, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Radiooncol, A-8036 Graz, Austria
[3] Med Univ Graz, Clin Inst Med & Lab Diagnost, A-8036 Graz, Austria
[4] Med Univ Salzburg, Dept Internal Med, Salzburg, Austria
关键词
D O I
10.1158/1078-0432.CCR-05-2055
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cyclooxygenase-2 (COX-2) is involved in carcinogenesis, immune response suppression, apoptosis inhibition, angiogenesis, and tumor cell invasion and metastasis. The gene for COX-2, designated as PTGS2, carries a common polymorphism at position 8473 in the 3'-untranslated region (PTGS2 8473T>C), which has been associated with susceptibility to malignant disease. To investigate the role of this polymorphism for breast cancer, we determined the prevalence of PTGS2 genotypes in 500 women with breast cancer and 500 sex- and age-matched healthy control subjects. Homozygous carriers of the 8473-CC genotype were more frequent among patients (12.4%) than among controls (6.6%; P = 0.002). The odds ratio for carriers of this genotype for breast cancer was 2.1 (95% confidence interval, 1.3-3.3). Among patients, estrogen receptor positivity was less frequent among carriers of a CC genotype (63.9%) than among carriers of aTT or TC genotype (76.9%; P = 0.028). Tumor size, histologic grade, presence of primary lymph node metastases, progesterone receptor positivity, or age at diagnosis were not associated with PTGS2 genotypes. We conclude that the homozygous PTGS2 8473-CC genotype may be associated with breast cancer risk.
引用
收藏
页码:1392 / 1394
页数:3
相关论文
共 22 条
[1]   The role of COX-2 inhibition in breast cancer treatment and prevention [J].
Arun, B ;
Goss, P .
SEMINARS IN ONCOLOGY, 2004, 31 (02) :22-29
[2]   Potential use of COX-2-aromatase inhibitor combinations in breast cancer [J].
Bundred, NJ ;
Barners, NLP .
BRITISH JOURNAL OF CANCER, 2005, 93 (Suppl 1) :S10-S15
[3]   Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer [J].
Campa, D ;
Zienolddiny, S ;
Maggini, V ;
Skaug, V ;
Haugen, A ;
Canzian, F .
CARCINOGENESIS, 2004, 25 (02) :229-235
[4]   Matlnspector and beyond: promoter analysis based on transcription factor binding sites [J].
Cartharius, K ;
Frech, K ;
Grote, K ;
Klocke, B ;
Haltmeier, M ;
Klingenhoff, A ;
Frisch, M ;
Bayerlein, M ;
Werner, T .
BIOINFORMATICS, 2005, 21 (13) :2933-2942
[5]   The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency [J].
Cok, SJ ;
Morrison, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (25) :23179-23185
[6]   Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer [J].
Cox, DG ;
Pontes, C ;
Guino, E ;
Navarro, M ;
Osorio, A ;
Canzian, F ;
Moreno, V .
BRITISH JOURNAL OF CANCER, 2004, 91 (02) :339-343
[7]  
Denkert Carsten, 2004, Clin Breast Cancer, V4, P428, DOI 10.3816/CBC.2004.n.006
[8]   A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans [J].
Esterbauer, H ;
Schneitler, C ;
Oberkofler, H ;
Ebenbichler, C ;
Paulweber, B ;
Sandhofer, F ;
Ladurner, G ;
Hell, E ;
Strosberg, AD ;
Patsch, JR ;
Krempler, F ;
Patsch, W .
NATURE GENETICS, 2001, 28 (02) :178-183
[9]  
Hamajima Nobuyuki, 2001, Asian Pac J Cancer Prev, V2, P57
[10]   Vienna RNA secondary structure server [J].
Hofacker, IL .
NUCLEIC ACIDS RESEARCH, 2003, 31 (13) :3429-3431